DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kato, Y.
Right arrow Articles by Nishino, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kato, Y.
Right arrow Articles by Nishino, A.

Vol. 28, Issue 10, 1146-1148, October 2000

SHORT COMMUNICATION
Both cMOAT/MRP2 and Another Unknown Transporter(s) Are Responsible for the Biliary Excretion of Glucuronide Conjugate of the Nonpeptide Angiotensin II Antagonist, Telmisaltan

Yukio Kato, Takashi Igarashi, Yuichi Sugiyama, and Akiko Nishino

Graduate School of Pharmaceutical Sciences
University of Tokyo
Tokyo, Japan (Y.K.,Y.S.)
CREST, Japan Science and
Technology Corporation (Y.K.,Y.S.)
and Department of Drug
Metabolism and Pharmacokinetics,
Kawanishi Pharma Research Institute,
Nippon Boehringer Ingelheim
Co., Ltd. (A.N. and T.I)

Canalicular multispecific organic anion transporter (cMOAT/MRP2) is known to play a major role in the transport of anionic xenobiotics including many types of glucuronide and glutathione conjugates across the bile canalicular membrane. In the present study, the biliary excretion of telmisartan (BIBR 277) and its glucuronide was examined in Sprague-Dawley rats (SDRs) and also in mutant strain Eisai-hyperbilirubinemic rats (EHBR), which have a hereditary defect in cMOAT/MRP2. Only a minimal difference was observed in the time profile of the plasma concentration of total radioactivity after administration of an i.v. bolus of BIBR 277. About 45% of the administered dose was excreted into bile up to 240 min in both strains, most of the radioactivity in the bile being BIBR 277 glucuronide. No significant difference was observed in the biliary excretion of BIBR 277 and its glucuronide between SDRs and EHBR although the plasma disappearance of BIBR 277 glucuronide was delayed in EHBR. To explain these data, the extent of glucuronidation of BIBR 277 by liver microsomes was examined in both strains. The Vmax value for the formation of BIBR 277 glucuronide was 2 to 3 times higher in EHBR than in SDRs, whereas both strains had similar Km values. After an i.v. bolus administration of BIBR 277 glucuronide, its plasma disappearance was delayed in EHBR, the biliary clearance in EHBR being about half that in SDRs. These results suggest that BIBR 277 glucuronide is transported by both cMOAT/MRP2 and another transporter that is also expressed in EHBR, and that the BIBR 277 glucuronidation is enhanced in EHBR, resulting in comparable excretion of glucuronide in both strains.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
N. Ishiguro, K. Maeda, A. Saito, W. Kishimoto, S. Matsushima, T. Ebner, W. Roth, T. Igarashi, and Y. Sugiyama
Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide
Drug Metab. Dispos., April 1, 2008; 36(4): 796 - 805.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
I. S. Westley, L. R. Brogan, R. G. Morris, A. M. Evans, and B. C. Sallustio
ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE
Drug Metab. Dispos., February 1, 2006; 34(2): 261 - 266.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Ogawa, R. Kishi, K. Mihara, H. Takahashi, A. Takagi, N. Matsumoto, K. Masuhara, K. Nakazawa, F. Miyake, S. Kobayashi, et al.
Population Pharmacokinetic and Pharmacodynamic Analysis of a Class IC Antiarrhythmic, Pilsicainide, in Patients With Cardiac Arrhythmias
J. Clin. Pharmacol., January 1, 2006; 46(1): 59 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Tahara, H. Kusuhara, E. Fuse, and Y. Sugiyama
P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION
Drug Metab. Dispos., July 1, 2005; 33(7): 963 - 968.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Kobayashi, H. Saitoh, M. Kobayashi, K. Tadano, Y. Takahashi, and T. Hirano
Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in Rats
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1029 - 1035.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z.-S. Chen, R. W. Robey, M. G. Belinsky, I. Shchaveleva, X.-Q. Ren, Y. Sugimoto, D. D. Ross, S. E. Bates, and G. D. Kruh
Transport of Methotrexate, Methotrexate Polyglutamates, and 17{beta}-Estradiol 17-({beta}-D-glucuronide) by ABCG2: Effects of Acquired Mutations at R482 on Methotrexate Transport
Cancer Res., July 15, 2003; 63(14): 4048 - 4054.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. J. Cherrington, D. P. Hartley, N. Li, D. R. Johnson, and C. D. Klaassen
Organ Distribution of Multidrug Resistance Proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and Hepatic Induction of Mrp3 by Constitutive Androstane Receptor Activators in Rats
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 97 - 104.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.